Multicentric Castleman disease
MONDO:0019754Multicentric castleman disease (MCD) is an aggressive form of Castleman disease that mostly results from human herpesvirus 8 (HHV8) infection. It manifests by fever, diffuse lymphadenopathy, hepatosplenomegaly, Involvement of the respiratory system and increased C-reactive protein.
Also known as: HHV-8-associated multicentric Castleman disease, Human herpesvirus-8-associated multicentric Castleman disease, MCD, multicentric Angiofollicular lymphoid hyperplasia, multicentric Castleman's disease, idiopathic multicentric Castleman's disease, multicentric plasma cell variant of Castleman's disease
1487 clinical trials for this condition and its sub-types, 13 tagged with Multicentric Castleman disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New drug cocktail shows promise for rare HIV-Linked cancer
Disease control OngoingThis early-phase trial tested whether combining two anti-cancer drugs, pomalidomide (taken as a pill) and liposomal doxorubicin (given through an IV), is safe and tolerable for people with advanced or hard-to-treat Kaposi sarcoma. The study enrolled 62 adults, including those wit…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental drug combo tested for rare, deadly castleman disease
Disease control OngoingThis study looks at a rare disease called KSHV-associated multicentric Castleman's disease (MCD), caused by a virus. Researchers are testing several drug combinations, including chemotherapy and antivirals, to see if they can control the disease. The study also tracks how the dis…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Rapamycin drug tested for rare castleman disease
Disease control OngoingThis phase 2 study tests the drug sirolimus (rapamycin) in 7 people with idiopathic multicentric Castleman disease who have not improved with standard therapy. The goal is to see if sirolimus can improve symptoms like fatigue, fever, and night sweats, and shrink enlarged lymph no…
Phase 2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Hidden bone loss: HIV and cancer patients under the scanner
Knowledge-focused OngoingThis study looks at why people with HIV and certain cancers caused by KSHV (Kaposi sarcoma herpesvirus) may lose bone density faster. Researchers will review past CT scans and health records from 40 adults treated at the NIH between 2005 and 2020. The goal is to find factors link…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Scientists hunt for genetic clues in rare blood disorders
Knowledge-focused PausedThis study looks at the genetic makeup of rare blood diseases like Castleman disease and Langerhans cell histiocytosis. Researchers will analyze blood or tissue samples from 135 participants to find genetic changes that could be targeted by existing or experimental therapies. The…
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC